Sofia D. Merajver mainly focuses on Breast cancer, Cancer research, Cancer, Pathology and Inflammatory breast cancer. The various areas that she examines in her Breast cancer study include Gynecology and Radiation therapy. Her research integrates issues of Oncology, Ovarian cancer, Obstetrics, Genetic testing and Risk factor in her study of Gynecology.
Her work carried out in the field of Cancer research brings together such families of science as Carcinogenesis, RhoC GTP-Binding Protein, RhoC and Transfection. Her work on Carcinoma and Immunohistochemistry as part of her general Pathology study is frequently connected to Copper deficiency and Blood Collection Tube, thereby bridging the divide between different branches of science. Her Inflammatory breast cancer research includes themes of End results, Gerontology, Phenotype, Immunology and Transplantation.
Sofia D. Merajver focuses on Breast cancer, Cancer, Cancer research, Internal medicine and Oncology. Sofia D. Merajver specializes in Breast cancer, namely Inflammatory breast cancer. Her study explores the link between Cancer and topics such as Family medicine that cross with problems in Genetic counseling.
Sofia D. Merajver works mostly in the field of Cancer research, limiting it down to concerns involving RhoC and, occasionally, Motility. Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology. Sofia D. Merajver conducted interdisciplinary study in her works that combined Oncology and Risk assessment.
Sofia D. Merajver mainly investigates Cancer, Breast cancer, Cancer research, Internal medicine and Oncology. Her studies in Cancer integrate themes in fields like SNP, Computational biology and Family medicine. Her primary area of study in Breast cancer is in the field of Inflammatory breast cancer.
In the subject of general Inflammatory breast cancer, her work in RhoC GTP-Binding Protein is often linked to North africa, thereby combining diverse domains of study. The Cancer research study combines topics in areas such as Gene expression, Cancer cell, Triple-negative breast cancer, Drug and RhoC. Her studies deal with areas such as Germline, Placebo, Tamoxifen, Estrogen receptor and Cohort as well as Oncology.
Sofia D. Merajver spends much of her time researching Breast cancer, Cancer, Internal medicine, Oncology and Cancer research. Her study on Metastatic breast cancer is often connected to African american as part of broader study in Breast cancer. Her Oncology research is multidisciplinary, incorporating perspectives in Germline, Ovarian cancer, Estrogen receptor and Genetic testing.
Her Cancer research study combines topics in areas such as Cell, Cell migration, Cancer cell, Inflammatory breast cancer and RhoC. Her Cancer cell research integrates issues from Carcinogenesis, Cancer stem cell and Primary tumor, Metastasis. The study incorporates disciplines such as Survival pathways, Oncogene and Library science in addition to Inflammatory breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.
S.V. Tavtigian;J. Simard;J. Rommens;F. Couch.
Nature Genetics (1996)
BRCA1 regulates human mammary stem/progenitor cell fate
Suling Liu;Christophe Ginestier;Emmanuelle Charafe-Jauffret;Hailey Foco.
Proceedings of the National Academy of Sciences of the United States of America (2008)
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Sofia D. Merajver;Trinh M. Pham;Rosemarie F. Caduff;Martha Chen.
Nature Genetics (1995)
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
S. Dawood;S. D. Merajver;P. Viens;P. B. Vermeulen.
Annals of Oncology (2011)
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Mary B. Daly;Robert Pilarski;Michael Berry;Saundra S. Buys.
Journal of The National Comprehensive Cancer Network (2017)
Assessment and Counseling for Women With a Family History of Breast Cancer: A Guide for Clinicians
Kent F. Hoskins;Jill E. Stopfer;Kathleen A. Calzone;Sofia D. Merajver.
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Steven A. Narod;Marie Pierre Dubé;Jan Klijn;Jan Lubinski.
Journal of the National Cancer Institute (2002)
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Quintin Pan;Celina G. Kleer;Kenneth L. Van Golen;Jennifer Irani.
Cancer Research (2002)
BRCA2 germline mutations in male breast cancer cases and breast cancer families.
Fergus J. Couch;Linda M. Farid;Michelle L. DeShano;Sean V. Tavtigian.
Nature Genetics (1996)
RhoC GTPase, a Novel Transforming Oncogene for Human Mammary Epithelial Cells That Partially Recapitulates the Inflammatory Breast Cancer Phenotype
Kenneth L. van Golen;Zhi-Fen Wu;Xiao Tan Qiao;Li Wei Bao.
Cancer Research (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: